Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1973 1
1975 2
1976 3
1977 2
1978 2
1980 2
1981 2
1982 2
1983 1
1984 6
1985 4
1986 6
1987 3
1988 9
1989 9
1990 6
1991 10
1992 11
1993 13
1994 14
1995 12
1996 3
1997 11
1998 10
1999 12
2000 14
2001 19
2002 14
2003 23
2004 19
2005 17
2006 23
2007 35
2008 37
2009 25
2010 34
2011 41
2012 33
2013 27
2014 37
2015 44
2016 51
2017 32
2018 54
2019 61
2020 62
2021 76
2022 87
2023 90
2024 69
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,056 results

Results by year

Filters applied: . Clear all
Page 1
Development of a WHO growth reference for school-aged children and adolescents.
de Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann J. de Onis M, et al. Among authors: nishida c. Bull World Health Organ. 2007 Sep;85(9):660-7. doi: 10.2471/blt.07.043497. Bull World Health Organ. 2007. PMID: 18026621 Free PMC article.
For BMI-for-age across all centiles the magnitude of the difference between the two curves at age 5 years is mostly 0.0 kg/m(2) to 0.1 kg/m(2). At 19 years, the new BMI values at +1 standard deviation (SD) are 25.4 kg/m(2) for boys and 25.0 kg/m(2) for …
For BMI-for-age across all centiles the magnitude of the difference between the two curves at age 5 years is mostly 0.0 kg/m(2) to 0. …
Vaccine Therapy for Heart Failure Targeting the Inflammatory Cytokine Igfbp7.
Katoh M, Nomura S, Yamada S, Ito M, Hayashi H, Katagiri M, Heryed T, Fujiwara T, Takeda N, Nishida M, Sugaya M, Kato M, Osawa T, Abe H, Sakurai Y, Ko T, Fujita K, Zhang B, Hatsuse S, Yamada T, Inoue S, Dai Z, Kubota M, Sawami K, Ono M, Morita H, Kubota Y, Mizuno S, Takahashi S, Nakanishi M, Ushiku T, Nakagami H, Aburatani H, Komuro I. Katoh M, et al. Among authors: nishida m. Circulation. 2024 Jul 30;150(5):374-389. doi: 10.1161/CIRCULATIONAHA.123.064719. Epub 2024 Jul 11. Circulation. 2024. PMID: 38991046
Abstracts from the 3rd International Genomic Medicine Conference (3rd IGMC 2015) : Jeddah, Kingdom of Saudi Arabia. 30 November - 3 December 2015.
Shay JW, Homma N, Zhou R, Naseer MI, Chaudhary AG, Al-Qahtani M, Hirokawa N, Goudarzi M, Fornace AJ Jr, Baeesa S, Hussain D, Bangash M, Alghamdi F, Schulten HJ, Carracedo A, Khan I, Qashqari H, Madkhali N, Saka M, Saini KS, Jamal A, Al-Maghrabi J, Abuzenadah A, Chaudhary A, Al Qahtani M, Damanhouri G, Alkhatabi H, Goodeve A, Crookes L, Niksic N, Beauchamp N, Abuzenadah AM, Vaught J, Budowle B, Assidi M, Buhmeida A, Al-Maghrabi J, Buhmeida A, Assidi M, Merdad L, Kumar S, Miura S, Gomez K, Carracedo A, Rasool M, Rebai A, Karim S, Eldin HFN, Abusamra H, Alhathli EM, Salem N, Al-Qahtani MH, Kumar S, Faheem H, Agarwa A, Nieschlag E, Wistuba J, Damm OS, Beg MA, Abdel-Meguid TA, Mosli HA, Bajouh OS, Abuzenadah AM, Al-Qahtani MH, Coskun S, Abu-Elmagd M, Buhmeida A, Dallol A, Al-Maghrabi J, Hakamy S, Al-Qahtani W, Al-Harbi A, Hussain S, Assidi M, Al-Qahtani M, Abuzenadah A, Ozkosem B, DuBois R, Messaoudi SS, Dandana MT, Mahjoub T, Almawi WY, Abdalla S, Al-Aama MN, Elzawahry A, Takahashi T, Mimaki S, Furukawa E, Nakatsuka R, Kurosaka I, Nishigaki T, Nakamura H, Serada S, Naka T, Hirota S, Shibata T, Tsuchihara K, Nishida T, Kato M, Mehmood S, Ashraf NM, Asif A, Bilal M, Mehmood MS, H… See abstract for full author list ➔ Shay JW, et al. Among authors: nishida t. BMC Genomics. 2016 Jul 20;17 Suppl 6(Suppl 6):487. doi: 10.1186/s12864-016-2858-0. BMC Genomics. 2016. PMID: 27454254 Free PMC article.
Shehab P29 Altered expression of CD200R1 on dendritic cells of patients with inflammatory bowel diseases: in silico investigations and clinical evaluations Mohammed F. Elshal, Kaleemuddin M., Alia M. Aldahlawi, Omar Saadah, J. Philip McCoy P30 Development of real ti …
Shehab P29 Altered expression of CD200R1 on dendritic cells of patients with inflammatory bowel diseases: in silico investigations and clini …
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Terashima M, Kim YW, Boku N, Chung HC, Chen JS, Ji J, Yeh TS, Chen LT, Ryu MH, Kim JG, Omori T, Rha SY, Kim TY, Ryu KW, Sakuramoto S, Nishida Y, Fukushima N, Yamada T, Bai LY, Hirashima Y, Hagihara S, Nakada T, Sasako M. Kang YK, et al. Among authors: nishida y. Lancet Gastroenterol Hepatol. 2024 Aug;9(8):705-717. doi: 10.1016/S2468-1253(24)00156-0. Epub 2024 Jun 18. Lancet Gastroenterol Hepatol. 2024. PMID: 38906161 Clinical Trial.
Adjuvant chemotherapy was administered as either tegafur-gimeracil-oteracil (S-1) at an initial dose of 40 mg/m(2) per dose orally twice per day for 28 consecutive days, followed by 14 days off per cycle, or capecitabine plus oxaliplatin consisting of an initial dose of in …
Adjuvant chemotherapy was administered as either tegafur-gimeracil-oteracil (S-1) at an initial dose of 40 mg/m(2) per dose orally tw …
Comparison of the treatment effectiveness between lemborexant and zolpidem tartrate extended-release for insomnia disorder subtypes defined based on polysomnographic findings.
Inoue Y, Nishida M, Kubota N, Koebis M, Taninaga T, Muramoto K, Ishikawa K, Moline M. Inoue Y, et al. Among authors: nishida m. J Clin Sleep Med. 2023 Mar 1;19(3):519-528. doi: 10.5664/jcsm.10378. J Clin Sleep Med. 2023. PMID: 36472134 Free PMC article. Clinical Trial.
CLINICAL TRIAL REGISTRATION: Registry: ClinicalTrials.gov; Name: Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1); URL: https://clinicaltrials.gov/ct2/show/record/NCT02783729; Identifier: NCT02783729. CITATION: Inou …
CLINICAL TRIAL REGISTRATION: Registry: ClinicalTrials.gov; Name: Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Ol …
The long elusive IgM Fc receptor, FcμR.
Kubagawa H, Oka S, Kubagawa Y, Torii I, Takayama E, Kang DW, Jones D, Nishida N, Miyawaki T, Bertoli LF, Sanders SK, Honjo K. Kubagawa H, et al. Among authors: nishida n. J Clin Immunol. 2014 Jul;34 Suppl 1(0 1):S35-45. doi: 10.1007/s10875-014-0022-7. Epub 2014 May 3. J Clin Immunol. 2014. PMID: 24793544 Free PMC article. Review.
Two Distinct Characteristics of Immune Microenvironment in Human Hepatocellular Carcinoma with Wnt/β-Catenin Mutations.
Aoki T, Nishida N, Kurebayashi Y, Sakai K, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Ueshima K, Minami Y, Tsurusaki M, Nakai T, Sakamoto M, Nishio K, Kudo M. Aoki T, et al. Among authors: nishida n. Liver Cancer. 2023 Oct 9;13(3):285-305. doi: 10.1159/000533818. eCollection 2024 Jun. Liver Cancer. 2023. PMID: 38894812 Free PMC article.
M-PAST score is better than MAST score for the diagnosis of active fibrotic nonalcoholic steatohepatitis.
Imajo K, Saigusa Y, Kobayashi T, Nagai K, Nishida S, Kawamura N, Doi H, Iwaki M, Nogami A, Honda Y, Kessoku T, Ogawa Y, Kirikoshi H, Yasuda S, Toyoda H, Hayashi H, Kokubu S, Utsunomiya D, Takahashi H, Aishima S, Kim BK, Tamaki N, Saito S, Yoneda M, Loomba R, Nakajima A. Imajo K, et al. Among authors: nishida s. Hepatol Res. 2023 Sep;53(9):844-856. doi: 10.1111/hepr.13927. Epub 2023 Jun 15. Hepatol Res. 2023. PMID: 37237426 Free PMC article.
Following the rule-in criteria, positive predictive values of F-CAST (81.8%) and M-PAST (81.8%) were higher than those of FAST (73.5%) and MAST (70.0%). Following the rule-out criteria, negative predictive values of F-CAST (90.5%) and M-PAST (90.9%) were higher than …
Following the rule-in criteria, positive predictive values of F-CAST (81.8%) and M-PAST (81.8%) were higher than those of FAST (73.5% …
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma.
Balcar L, Scheiner B, Fulgenzi CAM, D'Alessio A, Pomej K, Roig MB, Meyer EL, Che J, Nishida N, Lee PC, Wu L, Ang C, Krall A, Saeed A, Stefanini B, Cammarota A, Pressiani T, Abugabal YI, Chamseddine S, Wietharn B, Parisi A, Huang YH, Phen S, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, von Felden J, Schulze K, Silletta M, Trauner M, Samson A, Wege H, Piscaglia F, Galle PR, Stauber R, Kudo M, Singal AG, Itani A, Ulahannan SV, Parikh ND, Cortellini A, Kaseb A, Rimassa L, Chon HJ, Pinato DJ, Pinter M. Balcar L, et al. Among authors: nishida n. JHEP Rep. 2023 Dec 12;6(2):100982. doi: 10.1016/j.jhepr.2023.100982. eCollection 2024 Feb. JHEP Rep. 2023. PMID: 38274490 Free PMC article.
1,056 results